• Measure Summary
  • NQMC:011141
  • 2015 Mar

Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment (liver transplant, resection, ablation, trans-arterial chemoembolisation [TACE] or systemic anti-cancer therapy [SACT]) who die within 30 days of definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011121
  • 2016 May

Sarcoma: proportion of patients with osteosarcoma who are under the age of 40 who undergo neo-adjuvant combination systemic anti-cancer therapy (SACT).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011264
  • 2016 Feb

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo diagnostic excision biopsy where the surgical pathology report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011270
  • 2016 Feb

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their diagnostic excision biopsy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011155
  • 2016 Jun

Testicular cancer: proportion of patients with stage I seminoma receiving adjuvant single dose carboplatin area under the curve of 7 mg/ml/min (AUC7), based on ethylene diamine tetra-acetic acid (EDTA) clearance, within 8 weeks of orchidectomy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011231
  • 2017 Feb

Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo PET CT prior to start of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011191
  • 2015 Sep

Lymphoma: proportion of patients with nodal, non-bulky stage 1a diffuse large B-cell lymphoma (DLBCL) who receive local radiotherapy, in combination with chemotherapy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011158
  • 2016 Jun

Testicular cancer: proportion of patients with stage I testicular non-seminomatous (or mixed) germ cell tumour (NSGCT) who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011175
  • 2016 Aug

Cervical cancer: proportion of patients with cervical cancer who have an MRI of the pelvis performed prior to definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011267
  • 2016 Feb

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo sentinel node biopsy (SNB) where the SNB report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011138
  • 2015 Mar

Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing either CT or MRI and with full information recorded.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011124
  • 2016 May

Sarcoma: proportion of patients with sarcoma who undergo surgical resection or oncological treatment with curative intent who die within 30 days of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011171
  • 2015 Jan

Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive curative oncological treatment who die within 30 days of treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011036
  • 2016 Aug

Endometrial cancer: proportion of patients with stage IB, grade 1 or 2, or stage IA, grade 3 endometrioid or mucinous endometrial cancer having adjuvant vaginal brachytherapy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011228
  • 2017 Feb

Lung cancer: proportion of patients with lung cancer who have a pathological diagnosis (including following surgical resection).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011102
  • 2016 Oct

Renal cancer: proportion of patients with renal cell carcinoma (RCC) undergoing systemic anti-cancer therapy (SACT) as their first treatment who have a histological diagnosis (confirmed by biopsy) before commencing treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011194
  • 2015 Sep

Lymphoma: proportion of patients with lymphoma undergoing rituximab based treatment who have hepatitis B, hepatitis C and HIV status checked prior to treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011188
  • 2015 Sep

Lymphoma: proportion of patients with lymphoma who are discussed at a multidisciplinary team (MDT) meeting within 6 weeks of diagnosis.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011221
  • 2016 Jul

Breast cancer: proportion of patients with invasive breast cancer who have a greater than or equal to 5% overall survival benefit of chemotherapy treatment predicted at 10 years that undergo adjuvant chemotherapy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011075
  • 2016 Jun

Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) who have a second TURBT or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial resection.

NHS Scotland; Scottish Cancer Taskforce